Literature DB >> 2574206

Tumor necrosis factor stimulates transcription of HIV-1 in human T lymphocytes, independently and synergistically with mitogens.

N Israël1, U Hazan, J Alcami, A Munier, F Arenzana-Seisdedos, F Bachelerie, A Israël, J L Virelizier.   

Abstract

We have investigated the effect of TNF, a cytokine produced during most immunologic and inflammatory reactions, on HIV genome expression in human T lymphocytes. A CD4+ human T cell line (J.Jhan) was transfected with vectors permitting the expression of the chloramphenicol acetyl transferase (CAT) gene under the control of the long terminal repeat (LTR) of HIV-1. rTNF was found to induce HIV LTR transactivation as intensely as PHA or phorbol esters. PHA enhanced TNF receptor expression in J.Jhan cells and acted synergistically with TNF on HIV LTR induction. TNF was also shown to induce well expression of a whole HIV provirus genome transfected into J.Jhan cells. The use of various CAT constructs carrying fragments of the HIV LTR, combined with bandshift assays, showed that TNF stimulates HIV transcription by acting on the kB-like enhancer element of the LTR through induction and/or activation of an NF-kB-like protein factor. Such findings are compatible with the hypothesis that TNF production participates in the pathogenesis of AIDS by enhancing HIV replication in T lymphocytes.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2574206

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  56 in total

Review 1.  Regulation of HIV-1 transcription.

Authors:  K A Roebuck; M Saifuddin
Journal:  Gene Expr       Date:  1999

2.  Vpr Enhances Tumor Necrosis Factor Production by HIV-1-Infected T Cells.

Authors:  Ferdinand Roesch; Léa Richard; Réjane Rua; Françoise Porrot; Nicoletta Casartelli; Olivier Schwartz
Journal:  J Virol       Date:  2015-09-23       Impact factor: 5.103

3.  Intracellular thiols regulate activation of nuclear factor kappa B and transcription of human immunodeficiency virus.

Authors:  F J Staal; M Roederer; L A Herzenberg; L A Herzenberg
Journal:  Proc Natl Acad Sci U S A       Date:  1990-12       Impact factor: 11.205

4.  Rational interleukin 2 therapy for HIV positive individuals: daily low doses enhance immune function without toxicity.

Authors:  E L Jacobson; F Pilaro; K A Smith
Journal:  Proc Natl Acad Sci U S A       Date:  1996-09-17       Impact factor: 11.205

5.  Induction of interleukin-1 and tumor necrosis factor alpha in brain cultures by human immunodeficiency virus type 1.

Authors:  J E Merrill; Y Koyanagi; J Zack; L Thomas; F Martin; I S Chen
Journal:  J Virol       Date:  1992-04       Impact factor: 5.103

6.  Contact with thymic epithelial cells as a prerequisite for cytokine-enhanced human immunodeficiency virus type 1 replication in thymocytes.

Authors:  M Rothe; L Chêne; M T Nugeyre; J Braun; F Barré-Sinoussi; N Israël
Journal:  J Virol       Date:  1998-07       Impact factor: 5.103

7.  The presence of tat protein or tumor necrosis factor alpha is critical for herpes simplex virus type 1-induced expression of human immunodeficiency virus type 1.

Authors:  W Popik; P M Pitha
Journal:  J Virol       Date:  1994-03       Impact factor: 5.103

8.  Anti-human cytomegalovirus activity of cytokines produced by CD4+ T-cell clones specifically activated by IE1 peptides in vitro.

Authors:  J L Davignon; P Castanié; J A Yorke; N Gautier; D Clément; C Davrinche
Journal:  J Virol       Date:  1996-04       Impact factor: 5.103

9.  Effects of interleukin-10 on human peripheral blood mononuclear cell responses to Cryptococcus neoformans, Candida albicans, and lipopolysaccharide.

Authors:  S M Levitz; A Tabuni; S H Nong; D T Golenbock
Journal:  Infect Immun       Date:  1996-03       Impact factor: 3.441

10.  High-level replication of human immunodeficiency virus in thymocytes requires NF-kappaB activation through interaction with thymic epithelial cells.

Authors:  L Chêne; M T Nugeyre; F Barré-Sinoussi; N Israël
Journal:  J Virol       Date:  1999-03       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.